Update date
30 Sep 2023
Shareable Research Card
Innovation Pharmaceuticals Inc. Share-based Payment Arrangement, Expense
This metric view shows Innovation Pharmaceuticals Inc. share-based payment arrangement, expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q3 2023
- Latest reported value
- $3,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Sep 2023
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q3 2023.
- Latest reported value on this page: $3,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Share-based Payment Arrangement, Expense
Latest reported share-based payment arrangement, expense: $3,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 20 Nov 2023.
Benchmark Context
How Share-based Payment Arrangement, Expense compares with peers
Innovation Pharmaceuticals Inc. is outside the visible top 120 companies for share-based payment arrangement, expense in the current sample.
Compared with
Compared with 120 companies reporting share-based payment arrangement, expense in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Share-based Payment Arrangement, Expense is down about 98% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2012 to 31 Mar 2026.
- Nearby companies in this sample: MICROSOFT CORP and Alphabet Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Innovation Pharmaceuticals Inc.: Share-based Payment Arrangement, Expense
Latest period: Q3 2023. Period end: 30 Sep 2023. Units: USD. Frequency: quarterly and annual.
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Metric Snapshot
- Latest value
- $3,000
- Coverage range
- 30 Jun 2012 - 30 Sep 2023
- Fact rows
- 36
What This Metric Tells You
- Shows the reported level of share-based payment arrangement, expense over 30 Jun 2012 - 30 Sep 2023.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 36 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Share-based Payment Arrangement, Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | MICROSOFT CORP (msft) | $11,974,000,000 | Year - 30 Jun 2025 | Open MICROSOFT CORP Share-based Payment Arrangement, Expense |
| 2 | Alphabet Inc. (googl) | $7,200,000,000 | Quarter - 31 Mar 2026 | Open Alphabet Inc. Share-based Payment Arrangement, Expense |
| 3 | NVIDIA CORP (nvda) | $6,386,000,000 | Year - 25 Jan 2026 | Open NVIDIA CORP Share-based Payment Arrangement, Expense |
| 4 | Meta Platforms, Inc. (meta) | $5,891,000,000 | Quarter - 31 Dec 2025 | Open Meta Platforms, Inc. Share-based Payment Arrangement, Expense |
| 5 | BANK OF AMERICA CORP /DE/ (bac) | $4,200,000,000 | Year - 31 Dec 2025 | Open BANK OF AMERICA CORP /DE/ Share-based Payment Arrangement, Expense |
| 6 | AMAZON COM INC (amzn) | $4,032,000,000 | Quarter - 31 Mar 2026 | Open AMAZON COM INC Share-based Payment Arrangement, Expense |
Metric Details
- Metric
- Share-based Payment Arrangement, Expense (AllocatedShareBasedCompensationExpense)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly and annual
- History range
- 30 Jun 2012 - 30 Sep 2023
- Facts on this page
- 36
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Innovation Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2023 | $32,000 | $3,000 | -$175,000 | -98% | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 20 Nov 2023 | 2024 | Q1 |
| Q2 2023 | $207,000 | $4,000 | -$181,000 | -98% | 01 Apr 2023 | 30 Jun 2023 | 10-K | 28 Sep 2023 | 2023 | FY |
| Q1 2023 | $388,000 | $4,000 | -$202,000 | -98% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 15 May 2023 | 2023 | Q3 |
| Q4 2022 | $590,000 | $21,000 | -$131,000 | -86% | 01 Oct 2022 | 31 Dec 2022 | 10-Q | 15 Feb 2023 | 2023 | Q2 |
| Q3 2022 | $721,000 | $178,000 | +$138,000 | +345% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 20 Nov 2023 | 2024 | Q1 |
| Q2 2022 | $583,000 | $185,000 | +$88,000 | +91% | 01 Apr 2022 | 30 Jun 2022 | 10-K | 28 Sep 2023 | 2023 | FY |
| Q1 2022 | $495,000 | $206,000 | +$165,000 | +402% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 15 May 2023 | 2023 | Q3 |
| Q4 2021 | $330,000 | $152,000 | +$121,000 | +390% | 01 Oct 2021 | 31 Dec 2021 | 10-Q | 15 Feb 2023 | 2023 | Q2 |
| Q3 2021 | $209,000 | $40,000 | +$26,000 | +186% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 10 Nov 2022 | 2023 | Q1 |
| Q2 2021 | $183,000 | $97,000 | 01 Apr 2021 | 30 Jun 2021 | 10-K | 28 Sep 2022 | 2022 | FY | ||
| Q1 2021 | $41,000 | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 13 May 2022 | 2022 | Q3 | |||
| Q4 2020 | $31,000 | 01 Oct 2020 | 31 Dec 2020 | 10-Q | 14 Feb 2022 | 2022 | Q2 | |||
| Q3 2020 | $14,000 | -$286,000 | -95% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 16 Nov 2020 | 2021 | Q1 | |
| Q3 2019 | $300,000 | -$300,000 | -50% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 13 Nov 2019 | 2020 | Q1 | |
| Q3 2018 | $600,000 | -$300,000 | -33% | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 08 Nov 2018 | 2019 | Q1 | |
| Q3 2017 | $900,000 | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 08 Nov 2017 | 2018 | Q1 | |||
| Q1 2017 | $336,000 | +$318,000 | +1767% | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 09 May 2017 | 2017 | Q3 | |
| Q4 2016 | $347,000 | -$85,000 | -20% | 01 Oct 2016 | 31 Dec 2016 | 10-Q | 09 Feb 2017 | 2017 | Q2 | |
| Q1 2016 | $18,000 | -$5,000 | -22% | 01 Jan 2016 | 31 Mar 2016 | 10-Q | 09 May 2017 | 2017 | Q3 | |
| Q4 2015 | $432,000 | +$125,000 | +41% | 01 Oct 2015 | 31 Dec 2015 | 10-Q | 09 Feb 2017 | 2017 | Q2 | |
| Q1 2015 | $23,000 | -$214,000 | -90% | 01 Jan 2015 | 31 Mar 2015 | 10-Q | 11 May 2015 | 2015 | Q3 | |
| Q4 2014 | $307,000 | +$78,000 | +34% | 01 Oct 2014 | 31 Dec 2014 | 10-Q | 09 Feb 2015 | 2015 | Q2 | |
| Q1 2014 | $237,000 | 01 Jan 2014 | 31 Mar 2014 | 10-Q | 11 May 2015 | 2015 | Q3 | |||
| Q4 2013 | $229,000 | 01 Oct 2013 | 31 Dec 2013 | 10-Q | 09 Feb 2015 | 2015 | Q2 | |||
| Q3 2013 | $26,000 | 01 Jul 2013 | 30 Sep 2013 | 10-Q | 10 Nov 2014 | 2015 | Q1 |
Innovation Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2023 | $207,000 | -$376,000 | -64% | 01 Jul 2022 | 30 Jun 2023 | 10-K | 28 Sep 2023 | 2023 | FY |
| 2022 | $583,000 | +$400,000 | +219% | 01 Jul 2021 | 30 Jun 2022 | 10-K | 28 Sep 2023 | 2023 | FY |
| 2021 | $183,000 | +$170,000 | +1308% | 01 Jul 2020 | 30 Jun 2021 | 10-K | 28 Sep 2022 | 2022 | FY |
| 2020 | $13,000 | -$287,000 | -96% | 01 Jul 2019 | 30 Jun 2020 | 10-K | 14 Sep 2020 | 2020 | FY |
| 2019 | $300,000 | -$100,000 | -25% | 01 Jul 2018 | 30 Jun 2019 | 10-K | 30 Sep 2019 | 2019 | FY |
| 2018 | $400,000 | -$961,000 | -71% | 01 Jul 2017 | 30 Jun 2018 | 10-K | 11 Sep 2018 | 2018 | FY |
| 2017 | $1,361,000 | +$648,000 | +91% | 01 Jul 2016 | 30 Jun 2017 | 10-K | 11 Sep 2017 | 2017 | FY |
| 2016 | $713,000 | +$313,000 | +78% | 01 Jul 2015 | 30 Jun 2016 | 10-K | 11 Sep 2017 | 2017 | FY |
| 2015 | $400,000 | 01 Jul 2014 | 30 Jun 2015 | 10-K | 11 Sep 2017 | 2017 | FY | ||
| 2013 | $519,000 | -$2,185,000 | -81% | 01 Jul 2012 | 30 Jun 2013 | 10-K | 15 Sep 2014 | 2014 | FY |
| 2012 | $2,704,000 | 01 Jul 2011 | 30 Jun 2012 | 10-K | 15 Sep 2014 | 2014 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.